Tower Research Capital (TRC)’s Orphazyme A/S ORPH Stock Holding History

Tower Research Capital (TRC)’s Portfolio ORPH Stock Details ORPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,425	Closed	-$8K	–	7105
2021 Q4	$8K	Sell	3,425 -10,431	-75%	-$36.8K	﹤0.01%	4877
2021 Q3	$57K	Sell	13,856 -12,358	-47%	-$63.6K	﹤0.01%	2852
2021 Q2	$193K	Buy	26,214 +26,162	+50,312%	+$211K	0.01%	1958
2021 Q1	$0	Buy	+52	New	+$640	﹤0.01%	5942

Other funds holding ORPH

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Tower Research Capital (TRC)'s ORPH Position: Q1 2022 in Review

Tower Research Capital (TRC) sold out of Orphazyme A/S (ORPH) in Q1 2022, closing a stake of 3,425 shares — an estimated $8K sold.

Tower Research Capital (TRC) first reported a position in ORPH in Q1 2021 and held it in 4 quarters. The position peaked at $193K in Q2 2021. 4 funds tracked by Wall St. Rank hold ORPH as of Q1 2022.

Tower Research Capital (TRC) reported no remaining Orphazyme A/S position as of Q1 2022 after selling out during the quarter.
Tower Research Capital (TRC) sold 3,425 Orphazyme A/S shares in Q1 2022, an estimated $8K.
Tower Research Capital (TRC) first reported a position in Orphazyme A/S in Q1 2021 and held it in 4 quarters.
Tower Research Capital (TRC)'s Orphazyme A/S position peaked at $193K in Q2 2021.
4 funds tracked by Wall St. Rank held Orphazyme A/S as of Q1 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2022, filed 12 May 2022.